Strong evidence now supports the adoption of cervical cancer prevention strategies that
explicitly focus on persistent infection with the causal agent, human papillomavirus (HPV) …

Background: High-risk human papillomavirus (hrHPV) testing to triage women with minor
cervical lesions generates many referrals. Purpose: To evaluate the accuracy of genotyping …

OBJECTIVE: To examine the influence that type of medical training and number of biopsies
have on sensitivity of colposcopically guided biopsies. METHODS: Among 408 women with …

Background Human papillomavirus vaccination and cervical screening are lacking in most
lower resource settings, where approximately 80% of more than 500 000 cancer cases …

Primary human papillomavirus (HPV) testing (without concurrent Pap tests) every 3 years is
under consideration in the United States as an alternative to the two recommended cervical …

Objective The 2019 American Society for Colposcopy and Cervical Pathology Risk-Based
Management Consensus Guidelines for the management of cervical cancer screening …

Objective In 2012, the US Preventive Services Task Force (USPSTF) and a consensus of 25
organizations endorsed concurrent cytology and human papillomavirus (HPV) testing …

Background It is estimated that 1%–2% of women develop cervical intraepithelial neoplasia
grade 2–3 (CIN 2–3) annually worldwide. The prevalence among women living with HIV is …

Background Vaginal pH is related to genital tract inflammation and changes in the bacterial
flora, both suggested cofactors for persistence of human papillomavirus (HPV) infection. To …

Background HPV testing is replacing cytology for cervical cancer screening because of
greater sensitivity and superior reassurance following negative tests for the dozen HPV …